for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ACADIA Pharmaceuticals Inc.

ACAD.OQ

Latest Trade

47.37USD

Change

-0.56(-1.17%)

Volume

139,787

Today's Range

47.37

 - 

48.75

52 Week Range

14.01

 - 

53.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

ACADIA Pharmaceuticals Says Pivotal Phase 3 Harmony Study Showed Pimavanserin Reduced Risk Of Psychotic Relapse

Dec 4 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 HARMONY STUDY SHOWED PIMAVANSERIN REDUCED RISK OF PSYCHOTIC RELAPSE.PIMAVANSERIN MET PRIMARY ENDPOINT OF STUDY BY SIGNIFICANTLY REDUCING RISK OF PSYCHOTIC RELAPSE BY 2.8 FOLD OVER PLACEBO.PIMAVANSERIN MET KEY SECONDARY ENDPOINT BY SIGNIFICANTLY REDUCING RISK OF DISCONTINUATION FOR ANY REASON BY 2.2 FOLD OVER PLACEBO.PIMAVANSERIN 34 MG WAS WELL TOLERATED WHEN GIVEN LONG-TERM IN ELDERLY POPULATION WITH SIGNIFICANT COMORBIDITIES.NUPLAZID (PIMAVANSERIN) NOT APPROVED FOR TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.MOST COMMON ADVERSE REACTIONS FOR NUPLAZID AND GREATER THAN PLACEBO INCLUDE PERIPHERAL EDEMA, NAUSEA, HALLUCINATION.

ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results

Oct 30 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.29.Q3 SALES $94.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $88.5 MILLION.SEES FY 2019 SALES $330 MILLION TO $340 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $326.8 MILLION -- REFINITIV IBES DATA.

Acadia Pharmaceuticals Prices Underwritten Public Offering Of 6.25 Mln Shares At $40/Shr

Sept 17 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 6.25 MILLION SHARES OF COMMON STOCK AT PRICE TO PUBLIC OF $40.00 PER SHARE.

Acadia Pharmaceuticals - Intends To Offer And Sell $250 Million Of Its Common Stock

ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - INTENDS TO OFFER AND SELL $250 MILLION OF ITS COMMON STOCK.

Acadia Pharmaceuticals Announces Pivotal Phase 3 Harmony Trial Stopped Early For Positive Efficacy As Pimavanserin Meets The Primary Endpoint In Patients With Dementia-Related Psychosis

Sept 9 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 HARMONY TRIAL STOPPED EARLY FOR POSITIVE EFFICACY AS PIMAVANSERIN MEETS THE PRIMARY ENDPOINT IN PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.ACADIA PHARMACEUTICALS INC - PHASE 3 HARMONY STUDY MET ITS PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN ACHIEVED ROBUST STATISTICAL SUPERIORITY OVER PLACEBO IN STUDY.ACADIA PHARMA - STUDY TO BE STOPPED EARLY BASED ON PRE-SPECIFIED STOPPING CRITERIA REQUIRING ONE-SIDED P-VALUE LESS THAN 0.0033 ON STUDY'S PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - COMPANY IS PLANNING TO MEET WITH FDA REGARDING A SUPPLEMENTAL NDA SUBMISSION IN 2020.

Acadia Pharma Reports Second Quarter Loss Per Share Of $0.38

July 31 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.38.Q2 SALES $83.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $72.6 MILLION.SEES FY 2019 SALES $320 MILLION TO $330 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.45 -- REFINITIV IBES DATA.ACADIA PHARMACEUTICALS - AT JUNE 30, 2019, ACADIA'S CASH, CASH EQUIVALENTS, AND INVESTMENT SECURITIES TOTALED $381.9 MILLION.2019 GAAP SG&A GUIDANCE IS INCREASED TO $300 MILLION TO $315 MILLION.

Acadia Pharma Says Pimavanserin Did Not Achieve Statistical Significance On Primary Endpoint

July 22 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 ENHANCE TRIAL OF PIMAVANSERIN AS ADJUNCTIVE TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - IN STUDY, SIGNIFICANT IMPROVEMENTS OBSERVED ON SECONDARY ENDPOINT OF PANSS NEGATIVE SYMPTOMS SCALE SUB-SCORE.

Acadia Pharmaceuticals Q1 Loss Per Share $0.59

May 1 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.59.Q1 SALES $63 MILLION VERSUS REFINITIV IBES ESTIMATE OF $60.7 MILLION.SEES FY 2019 SALES $280 MILLION TO $300 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.ACADIA PHARMACEUTICALS - AT MARCH 31, 2019, CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES TOTALED $414.3 MILLION, COMPARED TO $473.5 MILLION AT DEC 31, 2018.FY2019 REVENUE VIEW $291.2 MILLION -- REFINITIV IBES DATA.

Acadia Pharmaceuticals Says Co Submitted Update To Data Available Through Centers For Medicare And Medicaid Services Open Payments Database

March 6 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS - ON MARCH 5, CO SUBMITTED UPDATE TO DATA AVAILABLE THROUGH CENTERS FOR MEDICARE AND MEDICAID SERVICES OPEN PAYMENTS DATABASE.ACADIA PHARMACEUTICALS - UPDATE IS TO RECLASSIFY CERTAIN CATEGORIZATION INFORMATION REGARDING GENERAL PAYMENTS PROVIDED TO PHYSICIANS.ACADIA PHARMACEUTICALS SAYS UPDATE WILL BE REFLECTED IN PUBLICLY AVAILABLE DATA POSTED ON OPENPAYMENTSDATA.CMS.GOV ON JUNE 30 - SEC FILING.

Acadia Pharmaceuticals Reports Fourth Quarter Results

Feb 26 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 SALES $59.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $59.5 MILLION.Q4 LOSS PER SHARE $0.50.Q4 EARNINGS PER SHARE ESTIMATE $-0.55 -- REFINITIV IBES DATA.SEES 2019 NET SALES OF $275 MILLION TO $300 MILLION.ACADIA PHARMACEUTICALS - PLANS TO INITIATE TWO PHASE 3 TRIALS FOR PIMAVANSERIN AS ADJUNCTIVE TREATMENT FOR MDD IN FIRST HALF OF 2019.ACADIA PHARMACEUTICALS - AT DEC 31, 2018, CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES TOTALED $473.5 MILLION, COMPARED TO $341.3 MILLION AT DEC 31, 2017.NUPLAZID NET SALES ARE EXPECTED TO BE BETWEEN $275 MILLION AND $300 MILLION IN 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up